By the end of the program, participants will be able to:
- employ new approaches to leverage genomic tools to validate targets, streamline clinical trials, decrease late development attrition, and identify patient groups in the marketplace
- apply program concepts to inform decisions about R&D priorities and directions, evaluation of internal and external opportunities, and strategic planning
This intensive program will feature a combination of pre-work, lectures, panel discussions, case studies, and group work. There will be ample time for networking with program faculty and peers.
Program topic areas include:
- Applications of genetics in common and rare diseases
- Discovery and validation of new targets
- Moving from genes to function and phenotypes
- Identifying causal biomarkers for clinical development
- De-risking development by predicting potential adverse effects
- Patient segmentation to streamline clinical trials
- Strategic approach to companion diagnostics
- Regulatory implications of genetics-informed development
- Implications for increased use of genetics for patient-centric R&D
- Future state: new technologies and approaches
Who Should Participate?
The program is intended for mid- to senior-level scientific and business leaders who make operational, strategic or investment decisions related to drug discovery and development. It is most appropriate for professionals in the biotech and pharmaceutical industries, or related investing, venture capital, and other professional services.
Participants from functional areas including R&D, medical affairs, strategy and business development can benefit from this program. Typical titles include Director and above.
Program Dates: June 4-5, 2019
Program Fee: $3,650
Request More Information
Professor of Medicine, Harvard Medical School
Director, Center for Genomic Medicine at Massachusetts General Hospital
Co-Director, Medical and Genetics Program, Broad Institute of MIT and Harvard